NovaDel Pharma Inc. (OTC BB: NVDL), a specialty pharmaceutical company that develops oral spray formulations of marketed pharmaceutical products, today reported opening an original Investigational New Drug (IND) application with the United States Food and Drug Administration (FDA) for its lead development program Duromist™, its sildenafil oral spray product for the treatment of erectile dysfunction (ED).
